Scholarlink

Background <p>Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.</p> Objective <p>To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.</p> Methods <p>We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.</p> Results <p>69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6&#xa0;years, <i>p</i> = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, <i>p</i> = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (<i>p</i> = 0.0033), median progression free survival was 5.5 (95% CI 3.97–8.23) vs 15.3&#xa0;months (95% CI 8.97- 26.3) (<i>p</i> = 0.001) and median OS was 17.3 (95% CI 13.32–39.97) versus 43.0&#xa0;months (95% CI 30.81, NR) (<i>p</i> = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, <i>p</i> = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23&#xa0;months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (<i>p</i> = 0.017) and 5&#xa0;year OS was 36.1% vs. 75.8% (<i>p</i> = 0.034).</p> Conclusions <p>Our data confirms a poor outcome of AM in the Spanish population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

  • 期刊论文

  • 发表日期：

    2025年8月21日

查看全文
  • Maria Gonzalez-Cao,
  • Miguel-Ángel Berciano-Guerrero,
  • Eva Muñoz-Couselo,
  • José Luis Manzano,
  • Pablo Cerezuela-Fuentes,
  • Guillermo Crespo,
  • Ainara Soria,
  • Pablo Ayala de Miguel,
  • Lourdes Gutiérrez Sanz,
  • Carlos Aguado de la Rosa,
  • Almudena García Castaño,
  • Teresa Puértolas,
  • Enrique Espinosa,
  • Javier Medina,
  • Lorena Bellido,
  • Alfonso Berrocal,
  • Margarita Majem,
  • Rafael López Castro,
  • Luis Antonio Fernandez,
  • Francisco Garcia,
  • Maria Rodriguez de la Borbolla,
  • Salvador Martín Algarra,
  • Iván Márquez-Rodas

摘要

Background

Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.

Objective

To analyze the activity of immunotherapy in patients diagnosed with AM in Spain.

Methods

We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.

Results

69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97–8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32–39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).

Conclusions

Our data confirms a poor outcome of AM in the Spanish population.